UPDATE: UBS Upgrades MedAssets (MDAS) to Buy; RCM Growth To Accelerate

June 21, 2012 7:49 AM EDT
Get Alerts MDAS Hot Sheet
Price: $31.35 --0%

Rating Summary:
    8 Buy, 25 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade MDAS Now!
Join SI Premium – FREE
(Updated - June 21, 2012 11:41 AM EDT)

UBS upgraded MedAssets (NASDAQ: MDAS) from Neutral to Buy. PT raised from $14 to $18.

Analyst, Stephen Shankman, said, "In our view, MDAS’ Revenue Cycle Management (RCM) segment is set up to outperform in 2012 (vs. guidance) and RCM growth should accelerate over the next few years. We believe MDAS will benefit from increasing demand for RCM (including consulting) leveraged by recent internal operational changes. As such, we see the combination of accelerating momentum in the RCM segment combined with ongoing solid SCM execution helping drive the PE multiple toward our ~15% LT EPS growth rate."

For an analyst ratings summary and ratings history on MedAssets click here. For more ratings news on MedAssets click here.

Shares of MedAssets closed at $12.72 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Upgrades

Related Entities


Add Your Comment